- Home
- Â /Â Leap Therapeutics
Leap Therapeutics
Stock Price
$4.6
2024-10-29
Market Capitalization
$176.4 M
2024-10-29
Revenue
$1.5 M
FY, 2021
Leap Therapeutics Summary
Company Summary
- Overview
- Leap Therapeutics (formerly known as HealthCare Pharmaceuticals) is a biopharmaceutical company developing targeted and immuno-oncology therapeutics. It offers DKN-01, a humanized monoclonal antibody targeting the Dickkopf-1 protein; FL-301, a humanized monoclonal antibody targeting Claudin18.2; and other antibody programs targeting Claudin18.2/CD137 and GDF15.
- Type
- Public
- Status
- Active
- Founded
- 2011
- HQ
- Cambridge, MA, US | view all locations
- Website
- https://www.leaptx.com
- Cybersecurity rating
Table of Contents
Key People
Mark O'Mahony, Chief Manufacturing Officer
Gus Lawlor, Chief Operating Officer
Jason Baum, Chief Scientific Officer
Leap Therapeutics Financials
Summary Financials
- Net income (FY, 2024)
- ($67.6M)
- Cash (FY, 2024)
- $47.2M
- EBIT (FY, 2024)
- ($70.1M)
- Enterprise value
- $129.7M